# NMAD catalysts: NOMAD POWER SOLUTIONS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nmad/catalysts

> NOMAD POWER SOLUTIONS, INC. (NMAD) has no upcoming catalysts in this calendar. The latest recorded is the andersen trial start, May 15, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for NMAD?

NOMAD POWER SOLUTIONS, INC. (NMAD) has no upcoming catalysts in this calendar. The latest recorded is the andersen trial start, May 15, 2024. SEC Form 10-Q: "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." [Calendar and source filings](https://sec-api.dev/companies/nmad/catalysts)

Source: SEC Form 10-Q, accession 0001493152-26-023150, https://www.sec.gov/Archives/edgar/data/1335105/000149315226023150/form10-q.htm (retrieved 2026-11-12). Last confirmed 2026-05-14. Cite: https://sec-api.dev/companies/nmad/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | NOMAD POWER SOLUTIONS, INC. |
| Ticker | NMAD (Nasdaq) |
| SEC CIK | 1335105 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nmad |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 22, 2023 | [LB-100 trial start](https://sec-api.dev/pdufa/lb-100) | NMAD |  | completed | "On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1335105/000164117225009575/form10-q.htm)) |
| September 20, 2023 | [LB-100 trial start](https://sec-api.dev/pdufa/lb-100) | NMAD | ovarian clear cell carcinoma | completed | "September 20, 2023, we announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1335105/000149315226027286/form424b5.htm)) |
| May 15, 2024 | [Andersen trial start](https://sec-api.dev/pdufa/andersen) | NMAD | ovarian clear cell carcinoma | completed | "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1335105/000149315226023150/form10-q.htm)) |

## Drugs

- [Andersen](https://sec-api.dev/pdufa/andersen): ovarian clear cell carcinoma
- [LB-100](https://sec-api.dev/pdufa/lb-100): ovarian clear cell carcinoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nmad/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NMAD catalysts: NOMAD POWER SOLUTIONS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nmad/catalysts

```bibtex
@misc{secapidev_companies_nmad_catalysts_20261116,
  title        = {NMAD catalysts: NOMAD POWER SOLUTIONS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nmad/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nmad_catalysts_20261116","title":"NMAD catalysts: NOMAD POWER SOLUTIONS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nmad/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
